• Explore /
  • Poster
  • / ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).

ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Matthew Raymond Smith

Massachusetts General Hospital Cancer Center, Boston, MA

Matthew Raymond Smith , Chris Parker , Bertrand F. TOMBAL , Kurt Miller , Fred Saad , Fang Fang , Amily Zhang , Martin Kornacker , Celestia S. Higano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT02043678

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS5082)

DOI

10.1200/jco.2015.33.15_suppl.tps5082

Abstract #

TPS5082

Poster Bd #

69b

Abstract Disclosures

Similar Posters

First Author: Matthew R. Smith

First Author: Johann S. De Bono

Poster

2015 Genitourinary Cancers Symposium

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Alice Clement-Zhao

First Author: Simon J. Crabb